The drug delivery market size is projected to reach US$ 4,228.64 billion by 2031 from US$ 2,247.26 billion in 2023. The market is expected to register a CAGR of 8.7% during 2023–2031. Strategic developments and product launches is likely to remain key trends in the market.
Chronic diseases tend to worsen over time, creating a significant burden on patients, their families, and society. According to the International Diabetes Federation (IDF), about 425 million people were living with diabetes in 2017, and this number is expected to reach 629 million by 2045. Diabetes is a life-threatening chronic disease for which there is no specialized cure. Diabetes can lead to number of complications in different parts of the body, increasing the risk of premature death. Major complications associated with diabetes include kidney failure, heart attack, stroke, leg amputation, vision loss, and nerve damage. The number of diabetes cases has been increasing significantly worldwide.
The rising prevalence of chronic diseases has led to intensified research and development (R&D) in drug delivery systems in recent decades. Using a drug delivery system can help reduce the systemic side effects of drugs. Various drug delivery vehicles have been developed for targeted and controlled delivery of therapeutics for a wide range of chronic diseases, including myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson's, diabetes, cancer, atherosclerosis, and Alzheimer's. An appropriate drug delivery system can enhance the therapeutic efficacy of a drug by ensuring high drug bioavailability for an extended period. Targeted drug delivery systems (TDDS) release drugs in a controlled manner at a specific site in the body. Nanotechnology-based delivery systems are having a significant impact on cancer treatment. In addition to the types of the administration route, nanotherapeutic drug delivery systems (NDDS) offer several technological advantages, including increased drug circulation time, controlled and sustained drug release, prolonged half-life, improved biodistribution, and elevated intercellular drug concentration.
Patients with chronic diseases depend on ongoing drug treatment, which comes with a continuous risk of side effects. Creating effective delivery systems for specific drugs can help concentrate the medicines in affected areas, minimize overall side effects, and enhance patient outcomes. As a result, the rising prevalence of chronic and lifestyle diseases supports the expansion of the drug delivery market.
Major factors driving the drug delivery market growth include growing demand for non-invasive drug delivery systems, increasing R&D expenditures in pharmaceutical companies, and rising incidence of chronic diseases propel the market growth. However, high cost associated with development of drugs and delivery systems and product recalls in drug delivery systems hinder the market growth.
R&D is an essential part of any company’s business. According to a study "Total Global Pharmaceutical R&D Spending 2014–2028" by Matej Mikulic, spending on R&D in the global pharmaceutical industry amounted to US$ ~238 billion in 2021. Compared to other industries, pharmaceutical companies are more driven by the need to create innovative products and spend significant investment on R&D. This is mainly due to the time-limited patent protection of drugs and the resulting threat of a collapse in sales due to competition from generics and biosimilars. Pharmaceutical and medical device companies focus on R&D to introduce new molecules for various therapeutic applications with the most significant medical and commercial potential. Strong R&D capabilities also help them bring high-quality and innovative products to the market. R&D spending by biopharmaceutical companies has also increased over the years.
According to a study "Global Trends in R&D 2022" by IQVIA, 84 Novel Active Substances (NAS) were launched worldwide in 2021, which brings the total number of launches to 883 over the past 20 years. The US continues to be the country with the earliest and highest number of launches. 44 (over 60%) of the 72 NAS launched worldwide in 2021 were approved as a first-in-class medication by the FDA, and 40 (more than 50%) carried the orphan drug designation, indicating their use for treating rare diseases. Venture capital deals and investment flows in the US have increased in the past two years owing to the high interest in life sciences. The country recorded over 2,000 deals with a transaction value of US$ 47 billion in 2021. In addition, the 15 largest pharmaceutical companies spent US$ 133 billion in R&D in 2021, up by 44% since 2016.
Companies operating in the drug delivery market constantly focus on strategic developments such as collaboration, partnerships, agreements, and new product launches, which help them improve their sales. The new product launches are mainly directed toward increased security, user-friendly features, better dosing capabilities, etc., to attract a large patient base. Through improved dosing capabilities, drug delivery systems complement the therapeutic outcomes and increase the potential of disease management in home care settings. A few of the noteworthy developments in the drug delivery market are mentioned below.
• In June 2022, Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder in hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations in adults suffering from Parkinson’s disease, prescribed with a levodopa/dopa-decarboxylase inhibitor.
• In June 2022, EVERSANA and Accord BioPharma partnered to support the launch of CAMCEVI (leuprolide) 42 mg injection emulsion for the treatment of advanced prostate cancer in adults.
• In March 2023, Stevanato Group collaborated with Recipharm to develop and manufacture pre-fillable syringes that would be integrated into a new soft mist inhaler for inhaling sensitive biological products. The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Recipharm’s proprietary soft mist inhalers.
The growing number of such strategic developments and product launches are expected to invite new growth trends in the drug delivery market in the coming years.
Key segments that contributed to the derivation of the drug delivery market analysis are route of administration, distribution channel, and end user.
The geographic scope of the drug delivery market report is mainly divided into five regions: North America, Middle East & Africa, Asia Pacific, Europe, and South & Central America.
North America has dominated the market. According to the Centers for Disease Control and Prevention (CDC) reported that in 2022, nearly 37.3 million people in the US had diabetes. Type 1 diabetes accounted for approximately 3.75% of this total, which amounts to around 1.45 million people. As a result, the growing diabetic population in the country is expected to drive the demand for different drug delivery systems to treat diabetes patients.
The regional trends and factors influencing the Drug Delivery Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Drug Delivery Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 2,247.26 Billion |
| Market Size by 2031 | US$ 4,228.64 Billion |
| Global CAGR (2023 - 2031) | 8.7% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Route of Administration
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Drug Delivery Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Drug Delivery Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The drug delivery market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the drug delivery market are listed below:
The “Drug Delivery Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
The North America region held the largest share of in the drug delivery market 2023.
Factors such as rising incidence of chronic diseases, growing demand for non-invasive drug delivery systems, and increasing R&D expenditures in pharmaceutical companies propel the drug delivery market.
Strategic developments and product launches will be the trend in the drug delivery market.
The drug delivery market majorly consists of the players, including Pfizer Inc, Johnson & Johnson, Becton Dickinson and Co, Novo Nordisk AS, Boston Scientific Corp, Baxter International Inc, Gerresheimer AG, Kindeva drug delivery LP, GlaxoSmithKline Plc, Bausch Health Companies, Novartis AG, Sever Pharma Solutions, and Boehringer Ingelheim International.
The drug delivery market is expected to be valued at US$ 4,228.64 billion in 2031.
The drug delivery market is estimated to record a CAGR of 8.7% till 2031.
![](data:image/svg+xml;charset=utf-8,<svg height="60px" width="170px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="500px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="320px" width="500px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)